Dermatologic Manifestations of Aspergillosis Medication
- Author: Annie Chiu, MD; Chief Editor: William D James, MD more...
In aspergillosis, high-dose intravenous amphotericin B has traditionally been used to eradicate the underlying organism. However, voriconazole has been approved as a first-line agent in the treatment of invasive aspergillosis and is available in both parenteral and oral formulations. A multicenter, randomized, open-label trial comparing the efficacy of voriconazole to amphotericin B demonstrated better response rates, improved survival, and fewer severe adverse effects in those receiving voriconazole therapy.
Itraconazole, posaconazole, caspofungin, terbinafine, and micafungin have also been reportedly effective in some cases of aspergillosis. The length of treatment varies in the literature, but treatment is likely to be most effective if prolonged. Studies show posaconazole as an alternative treatment for invasive aspergillosis in patients previously resistant to or intolerant of other antifungal therapies. Combination antifungal therapies have also been used in patients with aspergillosis that is associated with a greater degree of treatment resistance.
The mechanism of action may involve an alteration of RNA and DNA metabolism or an intracellular accumulation of peroxide that is toxic to the fungal cell.
Polyene antibiotic produced by a strain of Streptomyces nodosus; can be fungistatic or fungicidal. Binds to sterols (eg, ergosterol) in fungal cell membrane, causing intracellular components to leak with subsequent fungal cell death.
Fungistatic activity. Synthetic triazole antifungal agent that slows fungal cell growth by inhibiting CYP-450–dependent synthesis of ergosterol, a vital component of fungal cell membranes.
Used for primary treatment of invasive aspergillosis and salvage treatment for infection with Fusarium species or Scedosporium apiospermum. A triazole antifungal that inhibits fungal CYP450–mediated 14 alpha-lanosterol demethylation, which is essential in fungal ergosterol biosynthesis.
Used to treat refractory invasive aspergillosis. First of a new class of antifungal drugs (glucan synthesis inhibitors). Inhibits synthesis of beta-(1,3)-D-glucan, an essential component of fungal cell wall.
Member of new class of antifungal agents, echinocandins, that inhibit cell wall synthesis. Inhibits synthesis of 1,3-beta-D-glucan, an essential fungal cell wall component not present in mammalian cells.
Triazole antifungal agent. Blocks ergosterol synthesis by inhibiting the enzyme lanosterol 14-alpha-demethylase and sterol precursor accumulation. This action results in cell membrane disruption. Available as oral susp (200 mg/5 mL). Indicated for prophylaxis of invasive Aspergillus infections in patients at high risk because of severe immunosuppression.
Ozer B, Kalaci A, Duran N, Dogramaci Y, Yanat AN. Cutaneous infection caused by Aspergillus terreus. J Med Microbiol. 2009 Jul. 58:968-70. [Medline].
Zhang QQ, Li L, Zhu M, Zhang CY, Wang JJ. Primary cutaneous aspergillosis due to Aspergillus flavus: a case report. Chin Med J (Engl). 2005 Feb 5. 118(3):255-7. [Medline].
Mohapatra S, Xess I, Swetha JV, et al. Primary cutaneous aspergillosis due to Aspergillus niger in an immunocompetent patient. Indian J Med Microbiol. 2009 Oct-Dec. 27(4):367-70. [Medline].
Larkin JA, Greene JN, Sandin RL, Houston SH. Primary cutaneous aspergillosis: case report and review of the literature. Infect Control Hosp Epidemiol. 1996 Jun. 17(6):365-6. [Medline].
Robinson A, Fien S, Grassi MA. Nonhealing scalp wound infected with Aspergillus niger in an elderly patient. Cutis. 2011 Apr. 87(4):197-200. [Medline].
Naidu J, Singh SM. Aspergillus chevalieri (Mangin) Thom and Church: a new opportunistic pathogen of human cutaneous aspergillosis. Mycoses. 1994 Jul-Aug. 37(7-8):271-4. [Medline].
Kim CW, Seo JS, Kim MK, Jun EJ, Choi JC, Choi BW. Secondary cutaneous aspergillosis disseminated from the lungs of a patient with asthma on 1 month steroid treatment. Diagn Microbiol Infect Dis. 2010 Jan. 66(1):104-7. [Medline].
Wheat LJ. Rapid diagnosis of invasive aspergillosis by antigen detection. Transpl Infect Dis. 2003 Dec. 5(4):158-66. [Medline].
Krishnan-Natesan S, Chandrasekar PH, Manavathu EK, Revankar SG. Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine. Diagn Microbiol Infect Dis. 2008 Dec. 62(4):443-6. [Medline].
Cooke FJ, Terpos E, Boyle J, Rahemtulla A, Rogers TR. Disseminated Aspergillus terreus infection arising from cutaneous inoculation treated with caspofungin. Clin Microbiol Infect. 2003 Dec. 9(12):1238-41. [Medline].
Koss T, Bagheri B, Zeana C, Romagnoli MF, Grossman ME. Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent. J Am Acad Dermatol. 2002 Jun. 46(6):945-7. [Medline].
Klein KC, Blackwood RA. Topical voriconazole solution for cutaneous aspergillosis in a pediatric patient after bone marrow transplant. Pediatrics. 2006 Aug. 118(2):e506-8. [Medline].
Cabral C, Francisco V, Cavaleiro C, et al. Essential Oil of Juniperus communis subsp. alpina (Suter) Celak Needles: Chemical Composition, Antifungal Activity and Cytotoxicity. Phytother Res. 2012 Feb 1. [Medline].
[Guideline] Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008 Feb 1. 46(3):327-60. [Medline].
Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002 Aug 8. 347(6):408-15. [Medline].
Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007 Jan 1. 44(1):2-12. [Medline].
Elder D, Elenitsas R, Jaworsky C, eds. Lever's Histopathology of the Skin. Philadelphia, Pa: Lippincott-Raven; 1997. 525-6.
Freedberg I, Eisen AZ, Wolff K, et al, eds. Fitzpatrick's Dermatology in General Medicine. 5th ed. New York, NY: McGraw-Hill; 1999. 1436-7.
Odom RB, James WD, Berger TG, eds. Andrews' Diseases of the Skin. Philadelphia, Pa: WB Saunders; 2000. 415.
Richardson MD, Warnock DW, eds. Fungal Infection. Diagnosis and Management. 2nd ed. Blackwell Science: Oxford, England; 1997. 113-30.